Many chronic inflammatory diseases can be improved by helminth
infection, but the mechanisms are poorly understood.
Allergy and
helminthiasis are both associated with Th2-like immune responses; thus, defining how
infection with parasites leads to reduced
allergy has been particularly challenging. We sought to better understand this conundrum by evaluating host-parasite interactions involved in Th2 immunity in human
schistosomiasis. Immune cells were cultured with schistosomes and the effect on CD23, an
IgE receptor associated with resistance in
schistosomiasis, was evaluated. Cells treated with schistosomes demonstrated reduced surface CD23 levels with a parallel accumulation of soluble (s) CD23 suggesting this
IgE receptor is proteolytically cleaved by the parasite. Consistent with this hypothesis, a schistosome-generated (SG)-sCD23 fragment of 15 kDa was identified. SG-sCD23 inhibited
IgE from binding to CD23 and FcεRI, but lacked the ability to bind CD21. These results suggested that schistosomes target
IgE-mediated immunity in immuno-evasive tactics. Based on its characteristics, we predicted that SG-sCD23 would function as an efficacious
allergy preventative. Treatment of human FcεRI-transgenic mice with recombinant (r) SG-sCD23 reduced the ability of human
IgE to induce an acute allergic response in vivo. In addition, an optimized form of rSG-sCD23 with an introduced point mutation at Asp258 (D258E)to stabilize
IgE binding had increased efficacy compared to native rSG-sCD23. Schistosome
infection may thus inhibit allergic-like protective immune responses by increasing soluble
IgE decoy receptors.
Allergy treatments based on this naturally occurring phenomenon may be highly effective and have fewer side effects with long-term use.